Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB26FXGVP
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,424
Award facts
- Contract value 100% obligated
- $3,424.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $3,424.46 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. This firm fixed-price delivery order was issued on October 27, 2025, with an ultimate completion date of November 18, 2025, with no set-aside designation applied. The award represents a single transaction under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to streamline pharmaceutical procurement across the Department of Defense.
DMS Pharmaceutical Group Inc. was selected as a single-award prime vendor contractor under the PPV-G GEN V program, which was formally awarded on November 13, 2025, with a ceiling value of $499,999,999 and a completion date of December 31, 2036. The indefinite delivery contract structure authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for an extensive range of pharmaceuticals including branded and generic prescription medications, biologics, and medical consumables to support Department of Defense healthcare facilities worldwide. This delivery order for Xolair, a biologic immunosuppressant treatment, exemplifies the company's role as a critical supplier within the federal military medical supply chain, with the contract enabling rapid fulfillment of diverse and specialized pharmaceutical requirements across global defense healthcare operations.
Quick answers
Who was awarded contract SPE2DB26FXGVP?
SPE2DB26FXGVP was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DB26FXGVP worth?
The government has obligated $3,424 on SPE2DB26FXGVP.
Is contract SPE2DB26FXGVP an order under another contract?
Yes. SPE2DB26FXGVP is a delivery order under SPE2DB25D9306, an indefinite delivery contract.
Was contract SPE2DB26FXGVP competed?
The extent of competition for SPE2DB26FXGVP was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award